Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 15, 2022 07:30 ET
|
Brickell Biotech, Inc.
Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING...
Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting
March 10, 2022 08:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., March 10, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by...
Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022
March 08, 2022 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by...
Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences
February 02, 2022 07:30 ET
|
Brickell Biotech, Inc.
Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism Agreement enhances Brickell’s...
Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 09, 2021 16:05 ET
|
Brickell Biotech, Inc.
Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients; plan to submit a New Drug Application (NDA) to...
Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021
November 01, 2021 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing...
Brickell Biotech Prices Public Offering of Common Stock
October 28, 2021 07:58 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing...
Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock
October 27, 2021 16:32 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing...
Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients
October 07, 2021 06:55 ET
|
Brickell Biotech, Inc.
Sofpironium bromide gel, 15% was generally well-tolerated Plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Management to host webcast and conference call today at 8:30 a.m. ET...
Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity
September 17, 2021 08:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing...